MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
{{output}}
Background: Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab befor... ...
